Therapeutic vaccines function by triggering a
body immune response against a disease. The global therapeutic vaccines market
was valued at USD 292 million in 2011. The introduction of therapeutic vaccines
has opened up new avenues in the field of chronic disease treatment and
prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy
drug to treat prostate cancer in men in 2010, which has encouraged rigorous
research and development initiatives by pharmaceutical companies to develop
novel vaccines for untapped disease segments.
As a result of these initiatives, many more therapeutic
vaccines are currently in the pipeline such as breast cancer vaccine, lung
cancer vaccine; Alzheimer’s vaccine, malaria vaccine, and diabetes vaccine are
expected to be introduced in the market during the period from 2012 to 2018.
The market is currently facing growth hindrances
as R&D approaches, and regulatory and reimbursement policies are
inconspicuous owing to the nascent nature of the market. However, regulatory
bodies are working enthusiastically to lay out policies and growth strategies,
due to the fact that it holds the potential to solve or curb chronic diseases,
with no currently available treatments, such as HIV AIDS.
our components hold imperative importance in
designing a therapeutic vaccine:
Antigens: These are substances that evoke an
immune response from the body and are responsible for the production of
antibodies
Adjuvants: These are immunological agents that
help in modifying the effects of a drug or vaccine. Companies are now engaged
in designing new adjuvants that will help in enhancing the immunogenicity of an
antigen
Cost effective production systems for vaccines
Designing innovative drug delivery devices to
enhance vaccine efficacy
The North American therapeutic vaccine market is
expected to generate the maximum revenue in the global market during the
forecasted period due to the presence of efficient R&D facilities and
sophisticated medical infrastructures. The market is segmented into three major
application segments namely oncology, infectious diseases and other chronic
disorders.
The therapeutic vaccine market with oncology applications market
held the majority of the market share in 2011, as most of the research and
development exercises are expected to be directed towards this segment during
2012 to 2018.
Merck and GSK have strong therapeutic vaccine
product pipelines and are expected to perform better during 2012 to 2018 than
their competitors who have fewer products in the pipeline. Some of the other
key players of the market include Sanofi-Pasteur, Cytos Biotechnology AG, and
Intellect Neurosciences.
This research report analyzes this market
depending on its market segments, major geographies, and current market trends.
Geographies analyzed under this research report include :-
North America ,Asia Pacific ,Europe ,Rest of the
World
Browse
All Market Research Report : http://www.transparencymarketresearch.com/
0 comments:
Post a Comment